Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis

Background/Aim: Non-alcoholic fatty liver disease is a major cause of liver-related morbidity and mortality. Metformin is a widely used medication and may have additional benefits beyond glycemic control. Liraglutide, a novel treatment for diabetes and obesity, also has beneficial effects on non-alcoholic steatohepatitis (NASH). Metformin and liraglutide have both benefited NASH treatment. However, no study has reported the effects of combination therapy with liraglutide and metformin on NASH. Materials and Methods: We investigated the in vivo effects of metformin and liraglutide on NASH in a methionine/choline-deficient (MCD) diet-fed C57BL/6JNarl mouse model. Serum triglyceride, alanine aminotransferase and alanine aminotransferase levels were documented. Histological analysis was performed according to the NASH activity grade. Results: After treatment with liraglutide and metformin, body weight loss improved, and the liver/body weight ratio decreased. The metabolic effects and liver injury improved. Liraglutide and metformin alleviated MCD-induced hepatic steatosis and injury. Histological analysis revealed that NASH activity was reduced. Conclusion: Our results provide evidence for the anti-NASH activity of liraglutide in combination with metformin. Liraglutide with metformin may offer the potential for a disease-modifying intervention for NASH.

[1]  Jeffrey W. Clark,et al.  Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies , 2023, The oncologist.

[2]  M. C. Samaan,et al.  Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review , 2023, Frontiers in Endocrinology.

[3]  Yangyang Li,et al.  Research progress of metformin in the treatment of liver fibrosis. , 2023, International immunopharmacology.

[4]  Zhi‐Gang She,et al.  Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction , 2023, Frontiers in Cardiovascular Medicine.

[5]  F. Alharbi,et al.  A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes , 2023, International journal of medical sciences.

[6]  M. Neuman,et al.  Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different , 2022, International journal of molecular sciences.

[7]  Yang Du,et al.  Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study , 2022, Molecular biomedicine.

[8]  J. Sheen,et al.  Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications , 2022, International journal of molecular sciences.

[9]  D. Pinato,et al.  NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Jun Liu,et al.  Increased risk of non-alcoholic fatty liver disease fibrosis is closely associated with osteoporosis in women but not in men with type 2 diabetes , 2022, Endocrine connections.

[11]  A. Ciudin,et al.  Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study , 2022, Frontiers in Endocrinology.

[12]  Jai-Sing Yang,et al.  MTH-3 sensitizes oral cancer cells to cisplatin via regulating TFEB. , 2022, The Journal of pharmacy and pharmacology.

[13]  K. So,et al.  Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway , 2022, Molecular Biology Reports.

[14]  A. Lujambio,et al.  Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. , 2022, Journal of hepatology.

[15]  Hassan ul Hussain,et al.  Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2022, Clinics and research in hepatology and gastroenterology.

[16]  Tannaz Jamialahmadi,et al.  Impact of fenofibrate on NAFLD/NASH: a genetic perspective. , 2022, Drug discovery today.

[17]  Yan-Ning Huang,et al.  Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro , 2022, Bioengineered.

[18]  B. Harvey.  NASH: regulatory considerations for clinical drug development and U.S. FDA approval , 2022, Acta Pharmacologica Sinica.

[19]  Juan A. Vasquez,et al.  Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT) , 2022, Diabetes, obesity & metabolism.

[20]  Ming-Wei Wang,et al.  GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis , 2021, Acta Pharmacologica Sinica.

[21]  Yunling Wen,et al.  Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy , 2021, Frontiers in Pharmacology.

[22]  Q. Zhang,et al.  [Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver]. , 2021, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[23]  T. Lan,et al.  Nobiletin Alleviates Non-alcoholic Steatohepatitis in MCD-Induced Mice by Regulating Macrophage Polarization , 2021, Frontiers in Physiology.

[24]  Hongbing Wang,et al.  Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC , 2021, International journal of molecular sciences.

[25]  Liang Zhao,et al.  Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway , 2021, Frontiers in Pharmacology.

[26]  He He,et al.  Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis , 2021, Frontiers in Endocrinology.

[27]  Yuanyuan Xiao,et al.  Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway , 2020, Frontiers in Cell and Developmental Biology.

[28]  M. Puig-Domingo,et al.  Obesity and GLP-1. , 2020, Minerva endocrinologica.

[29]  M. Cârșote,et al.  Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). , 2020, Experimental and therapeutic medicine.

[30]  A. Mithal,et al.  Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial) , 2020, Diabetologia.

[31]  Jing Yang,et al.  Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway , 2020, Peptides.

[32]  C. Mantzoros,et al.  Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis , 2020, Molecular metabolism.

[33]  S. Softic,et al.  Evolving Role for Pharmacotherapy in NAFLD/NASH , 2020, Clinical and translational science.

[34]  Pei-min Feng,et al.  The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. , 2020, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[35]  D. Iliopoulos,et al.  Pathophysiological Changes During Ischemia-reperfusion Injury in Rodent Hepatic Steatosis , 2020, In Vivo.

[36]  Ying Shi,et al.  Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. , 2020, The Journal of nutritional biochemistry.

[37]  C. Mantzoros,et al.  Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. , 2020, Diabetes & metabolism.

[38]  J. Jelsing,et al.  Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH , 2019, BMC Gastroenterology.

[39]  Caiyan Zhao,et al.  Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo. , 2019, Biochemical and biophysical research communications.

[40]  Xiaojun Xu,et al.  Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-α. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  G. Qin,et al.  Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[42]  Jie Shen,et al.  Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease , 2018, Bioscience reports.

[43]  C. Celsa,et al.  Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? , 2018, Pharmaceuticals.

[44]  N. Lundbom,et al.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study , 2018, Diabetes, obesity & metabolism.

[45]  L. Blonde,et al.  GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. , 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[46]  E. Tsochatzis,et al.  The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD) , 2018, Hormones.

[47]  C. Diéguez,et al.  Cooperative role of the glucagon‐like peptide‐1 receptor and β3‐adrenergic‐mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats , 2018, Acta physiologica.

[48]  A. Pocai,et al.  Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice , 2017, PloS one.

[49]  Ying-Ju Lin,et al.  Autophagy and its link to type II diabetes mellitus , 2017, BioMedicine.

[50]  Xin Sun,et al.  Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2017, Clinics and research in hepatology and gastroenterology.

[51]  I. Rusyn,et al.  Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[52]  A. Sanyal,et al.  Therapies in non‐alcoholic steatohepatitis (NASH) , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[53]  Y. Ni,et al.  Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease , 2016, International journal of molecular sciences.

[54]  J. Cegla.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study , 2016, Annals of clinical biochemistry.

[55]  K. Cusi,et al.  Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus , 2016, Clinical Diabetes and Endocrinology.

[56]  V. Ratziu.  Novel Pharmacotherapy Options for NASH , 2016, Digestive Diseases and Sciences.

[57]  Qianyue Xu,et al.  Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized and non‐randomized studies , 2016, Diabetes/metabolism research and reviews.

[58]  Guiyuan Ji,et al.  Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy , 2015, Lipids in Health and Disease.

[59]  Lulu Chen,et al.  Metformin and metabolic diseases: a focus on hepatic aspects , 2015, Frontiers of Medicine.

[60]  S. Sarin,et al.  World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. , 2014, Journal of clinical gastroenterology.

[61]  A. Kadayifci,et al.  Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. , 2014, World journal of hepatology.

[62]  N. Milić,et al.  Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism , 2014, Expert review of gastroenterology & hepatology.

[63]  C. Brenner,et al.  Non-alcoholic steatohepatitis: new insights from OMICS studies. , 2012, Current pharmaceutical biotechnology.

[64]  G. Ryan,et al.  Review of the therapeutic uses of liraglutide. , 2011, Clinical therapeutics.

[65]  A. Tran,et al.  Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial. , 2009, Gastroenterologie clinique et biologique.

[66]  R. Deutsch,et al.  A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis , 2005, Alimentary pharmacology & therapeutics.

[67]  G. Farr,et al.  Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial , 2004, Alimentary pharmacology & therapeutics.

[68]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[69]  J. N. dos Santos,et al.  Morphological Changes in Major Salivary Glands in Mice Treated With a Choline and Methionine Deficient Diet , 2022, In Vivo.

[70]  M. Baruah,et al.  Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus , 2011, Indian journal of endocrinology and metabolism.